Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: General Crude who wrote (4347)	5/19/1998 9:25:00 PM
From: Bhag Karamchandani	Respond to of 6136

ML factored in all expenses related to R&D and conducting trials on two drugs but totally discounted any new drug approvals till 2002. Based on their price projections (and assumptions ) there will little incentive for the shorts to cover their positions- in the near term, at least. AGPH exposure at the LA Cancer Conference appears to have been muted- in contrast to the promptitude with which they responded to Entremed's results- with Johnson appearing the same day on CNBC. Wonder why??